Population pharmacokinetics of vancomycin in adult and geriatric patients: Comparison of eleven approaches

International Journal of Clinical Pharmacology and Therapeutics

Volumn 48, Issue 8, 2010, Pages 525-533

  Sanchez J L ^a   Dominguez, A R ^b   Lane, J R ^b   Anderson, P O ^b   Capparelli, E V ^b   Cornejo Bravo, J M ^a  

^a UNIVERSIDAD AUTÓNOMA DE BAJA CALIFORNIA   (Mexico)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Geriatrics; NONMEM; Population pharmacokinetics; Vancomycin

Indexed keywords

VANCOMYCIN;

ACCURACY; ADULT; AGE; AGED; ARTICLE; BODY WEIGHT; COMPARTMENT MODEL; CONTROLLED STUDY; DATA BASE; DRUG BLOOD LEVEL; DRUG CLEARANCE; FEMALE; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; PHARMACOKINETICS; POPULATION; PREDICTION; RETROSPECTIVE STUDY; STATISTICAL ANALYSIS; VALIDATION STUDY;

EID: 77955684746     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP48525     Document Type: Article

References (27)

1. Ambrose PJ, Winter ME. Vancomycin. In: Basic clinical pharmacokinetics, 4th ed. Philadelphia: Lippincott Williams & Wilkins; 2004. p. 451-476.
2. American Thoracic Society and the Infectious Diseases Society of America. Guidelines for the Management of Adults with Hospital-acquired, Ventilator-associated, and Healthcare-associated Pneumonia. Am J Respir Crit Care Med. 2005; 171: 388-416.
3. Anderson PO, Ting J. Therapeutic Drug Monitorin System (TDMS): Version 6.5; 1986-2005; Healthware, Inc. San Diego, CA.
4. Bauer LA. Applied clinical pharmacokinetics. New Cork: McGraw Hill, Medical Publishing Division; 2001. p. 180-261.
5. Beal SL. NONMEM user's guides. NONMEM project group. University of California, San Francisco. 2008.
6. Birt JK, Chandler MH. Using clinical data to determine vancomycin dosing parameters. Ther Drug Monit. 1990; 12: 206-209.
7. Burton ME, Gentle DL, Vasko MR. Evaluation of a Bayesian method for predicting vancomycin dosing. DICP. 1989; 23: 294-300.
8. Cockcroft, DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976; 16: 31-41.
9. Culter NR, Naravag PK, Lesko JL et al. Vancomycin disposition: the importance of age. Clin Pharmacol Ther. 1984; 36: 803-810.
10. Devine BJ. Gentamicin therapy. DICP. 1974; 8: 650-655.
11. Ducharme MP, Slaughter RL, Edwards DJ. Vancomycin pharmacokinetics in a patient population: effect of age, gender and body weight. Ther Drug Monit. 1994; 16: 513-518.
12. Golper TA, Noonan HM Elzinga L et al. Vancomycin pharmacokinetics, renal handling and nonrenal clearances in normal human subjects. Clin Pharmacol Ther. 1988; 43: 565-570.
13. Jonsson EN, Karlsson MO. Xpose-an S-PLUSS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comput Methods Programs Biomed.1999; 58: 51-64.
14. Lee E, Winter ME, Boro MS. Comparing two predictive methods for determining serum vancomycin concentrations at a Veterans Affairs Medical Center. Am J Health Syst Pharm. 2006; 63: 1872-1875.
15. Leonard AE, Boro MS. Vancomycin pharmacokinetics in middle-age and elderly men. Am J Hosp Pharm. 1994; 51: 798-800.
16. Matzke GR, Mcgory RW, Halstentson CE. Pharmacokinetics of vancomycin in patients with various degrees of renal function. Antimicrob Agent Chemother. 1984; 25: 433-437.
17. Moise-Broder PA, Forrest A, Birmingham MC et al. Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections. Clin Pharmacokinet. 2004; 43: 925-942.
18. Murphy JD, Guillespie DE, Bateman CV. Predictability of vancomycin trough concentrations using seven approaches for estimating pharmacokinetic parameters. Am J Health Syst Pharm. 2006; 63: 2365-2370.
19. Rodvold KA, Blum RA, Fisher JH. Vancomycin pharmacokinetics in patients with various degree of renal function. Antimicrob Agents Chemother. 1988; 32: 848-852.
20. Rushing T, Ambrose P. Clinical application and evaluation of vancomycin dosing in adults. J. Pharm Technol. 2001; 17: 33-38.
21. Ryback MJ, Albretch LM, Boike SC et al. Nephrotoxicity of vancomycin, alone and with an aminoglycoside. J Antimicrob Chemother. 1990; 25: 679-687.
22. Salazar DE, Corcoran GB. Predicting creatinine clearance and renal drug clearance in obese patients from estimated fat-free body mass. Am J Med. 1988; 84: 1053-1060.
23. Santos Buelga D, Fernández de Gatta M, Herrera EV et al. Population pharmacokinetics analysis of vancomycin in patients with hematological malignancies. Antimicrob Agents Chemother. 2005; 49: 4931-4934.
24. Sheiner LB, Beal SL. Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm. 1981; 9: 503-512.
25. Vance-Bryan K, Rostchafer JC, Gilliard SS et al. A comparative assessment of vancomycin-associated nephrotoxicity in the young versus elderly hospitalizated patient. J Antimicrob Chemother. 1994; 33: 811-821.
26. Winter ME. Vamcomycin. In: Basic clinical pharmacokinetics. 3rd ed. Spokane: Applied Therapeutics; 1994: 474-499.
27. Yasuhara M, Iga T, Zenda H et al. Population pharmacokinetics of vancomycin in Japanese adult patients. Ther Drug Monit. 1998; 20: 139-148. (Pubitemid 28163195)